

Biophyll GmbH – Winkl 4 – D-84378 Dietersburg – Germany

To Whom it may concern


Dietersburg, 04.01.20120

Letter of intent

We have reviewed the features of SUSPENCE™, a product developed by Cellex srl – Piazzale delle Belle Arti, 2 – Rome (Italy), and we confirm that we intend to use it in our R&D activities, particularly for further validation of our product Acto2Hem (www.actohem.com).

Acto2Hem is currently developed under the EUROSTARS funding program with our partner company M BioserviceS GmbH. It is essential to the further technology development to use it also under the environment created by the SUSPENCE™ device. The planned start of our trials is March 2020.

Yours Sincerely



Biophyll GmbH
Winkl 4, D-84378 Dietersburg
Tel: 08565-964961
Fax: 08565-964963
Email: Biophyll@web.de

Dr. Peter Haeusl
Managing Director